MannKind Corporation

MNKD

$5.63

Name : MannKind Corporation

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,728,805,632.00

EPSttm : 0.1

MannKind Corporation

$5.63

1.92%

$0.11

Float Short %

8.79

Margin Of Safety %

-4

Put/Call OI Ratio

0.21

EPS Next Q Diff

EPS Last/This Y

0.09

EPS This/Next Y

-0.05

Price

5.63

Target Price

9.61

Analyst Recom

Performance Q

7.24

Relative Volume

0.43

Beta

0.76

Ticker: MNKD

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	MNKD	5.64	0.17	0.07	74456
2026-01-14	MNKD	5.62	0.17	0.12	74703
2026-01-15	MNKD	5.58	0.17	0.28	75070
2026-01-16	MNKD	5.22	0.18	0.08	75498
2026-01-20	MNKD	5.5	0.22	0.28	48802
2026-01-21	MNKD	5.72	0.22	0.23	53977
2026-01-22	MNKD	5.91	0.23	0.02	56863
2026-01-23	MNKD	5.46	0.22	0.35	59070
2026-01-26	MNKD	5.57	0.23	0.16	57575
2026-01-27	MNKD	5.59	0.23	0.28	57912
2026-01-28	MNKD	5.64	0.23	0.14	58359
2026-01-29	MNKD	5.8	0.23	0.15	60055
2026-01-30	MNKD	5.79	0.23	0.03	61496
2026-02-02	MNKD	5.98	0.23	0.09	60791
2026-02-03	MNKD	6.22	0.23	0.30	61478
2026-02-05	MNKD	5.52	0.23	0.02	62251
2026-02-09	MNKD	5.93	0.21	0.10	64788
2026-02-10	MNKD	5.84	0.21	0.16	65980
2026-02-11	MNKD	5.74	0.21	0.08	66015
2026-02-12	MNKD	5.62	0.21	0.10	66043
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	MNKD	5.65	-	-	0.19
2026-01-14	MNKD	5.61	-	-	0.19
2026-01-15	MNKD	5.58	-	-	0.19
2026-01-16	MNKD	5.22	-	-	0.19
2026-01-20	MNKD	5.50	-	-	0.19
2026-01-21	MNKD	5.72	-	-	0.19
2026-01-22	MNKD	5.90	-	-	0.19
2026-01-23	MNKD	5.46	-	-	0.19
2026-01-26	MNKD	5.57	-	-	0.19
2026-01-27	MNKD	5.59	-	-	0.19
2026-01-28	MNKD	5.65	-	-	0.19
2026-01-29	MNKD	5.80	-	-	0.19
2026-01-30	MNKD	5.79	-	-	0.19
2026-02-02	MNKD	6.00	-	-	0.19
2026-02-03	MNKD	6.22	-	-	0.19
2026-02-04	MNKD	5.78	-	-	0.19
2026-02-05	MNKD	5.52	-	-	0.19
2026-02-06	MNKD	5.78	-	-	0.19
2026-02-09	MNKD	5.93	-	-	0.19
2026-02-10	MNKD	5.84	-	-	0.19
2026-02-11	MNKD	5.74	-	-	0.19
2026-02-12	MNKD	5.63	-	-	0.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	MNKD	-6.05	0.85	8.62
2026-01-14	MNKD	-6.05	0.85	8.62
2026-01-15	MNKD	-6.05	0.85	8.62
2026-01-16	MNKD	-6.05	0.85	8.62
2026-01-20	MNKD	-5.21	0.59	8.62
2026-01-21	MNKD	-5.21	0.59	8.62
2026-01-22	MNKD	-5.21	0.59	8.62
2026-01-23	MNKD	-5.21	0.59	8.62
2026-01-26	MNKD	-5.21	0.58	8.62
2026-01-27	MNKD	-5.21	0.58	8.62
2026-01-28	MNKD	-5.21	0.58	9.15
2026-01-29	MNKD	-5.21	0.58	9.15
2026-01-30	MNKD	-5.21	0.58	9.15
2026-02-02	MNKD	-5.21	0.47	9.15
2026-02-03	MNKD	-5.21	0.47	9.15
2026-02-04	MNKD	-5.21	0.47	9.15
2026-02-05	MNKD	-5.21	0.47	9.15
2026-02-06	MNKD	-5.21	0.47	9.15
2026-02-09	MNKD	-5.21	-0.38	9.15
2026-02-10	MNKD	-5.21	-0.38	9.15
2026-02-11	MNKD	-5.21	-0.38	8.79
2026-02-12	MNKD	-5.21	-0.38	8.79
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

0.07

Avg. EPS Est. Current Quarter

0.03

Avg. EPS Est. Next Quarter

0.07

Insider Transactions

-5.21

Institutional Transactions

-0.38

Beta

0.76

Average Sales Estimate Current Quarter

100

Average Sales Estimate Next Quarter

110

Fair Value

5.39

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

26.2

Max Drawdown 5-Year %

-57.3

Target Price

9.61

P/E

59.7

Forward P/E

65.86

PEG

1.98

P/S

5.51

P/B

P/Free Cash Flow

40.45

EPS

0.09

Average EPS Est. Cur. Y

0.19

EPS Next Y. (Est.)

0.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.32

Relative Volume

0.43

Return on Equity vs Sector %

-93.5

Return on Equity vs Industry %

-77.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

MannKind Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 403

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

stock quote shares MNKD – MannKind Corporation Stock Price stock today

news today MNKD – MannKind Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch MNKD – MannKind Corporation yahoo finance google finance

stock history MNKD – MannKind Corporation invest stock market

stock prices MNKD premarket after hours

ticker MNKD fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MNKD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y